공지 • May 03
ICON Public Limited Company announced delayed 20-F filing On 05/01/2026, ICON Public Limited Company announced that they will be unable to file their next 20-F by the deadline required by the SEC. Price Target Changed • Mar 25
Price target decreased by 11% to US$132 Down from US$149, the current price target is an average from 13 analysts. New target price is 32% above last closing price of US$99.99. Stock is down 44% over the past year. The company is forecast to post earnings per share of US$6.46 for next year compared to US$9.60 last year. 공지 • Mar 11
An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC. An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025.
An undisclosed buyer completed the acquisition of an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Price Target Changed • Feb 12
Price target decreased by 9.1% to US$187 Down from US$206, the current price target is an average from 16 analysts. New target price is 134% above last closing price of US$80.08. Stock is down 56% over the past year. The company is forecast to post earnings per share of US$6.71 for next year compared to US$9.60 last year. 공지 • Feb 12
ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026 ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2026 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to US$146, the stock trades at a forward P/E ratio of 17x. Average trailing P/E is 37x in the Life Sciences industry in the US. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$258 per share. Buy Or Sell Opportunity • Jan 08
Now 22% undervalued Over the last 90 days, the stock has risen 2.6% to US$188. The fair value is estimated to be US$242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. 공지 • Dec 09
ICON plc Releases Findings from Two Biotech Sector Survey ICON plc released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. It positions China's presence as a positive signal for the global industry, with the findings highlighting how Western biotechs must adapt to maintain competitiveness and drive innovation. Funding remains a key challenge and 41% of organizations are actively seeking additional R&D funding, a 27% increase since 2023, highlighting ongoing financial pressures across the industry. Globally, the top three sources of funding are unchanged: large pharma partnerships, venture capital (VC), and government grants. However, the survey shows how VC funds have expanded their focus, with APAC biotechs stating VC funding was 60% of their current funding source versus 32% for US and 30% for Europe. This is leading some biotechs to explore innovative funding sources and ICON highlights the emerging models being increasingly adopted, including royalty financing, carve-outs, and crowdfunding. Since the last survey, access to talent is becoming more of a concern. This was more pronounced in APAC where responders were almost three times as likely to list talent shortages as having operational impact as their global counterparts (47% vs 18% in the US and 17% in Europe). The survey reveals leading next-generation modalities; notably, cell therapy has overtaken small molecules and is now most prominent, making up 40% of organizations' pipelines. Antibody drug conjugates (ADCs) and microbiome therapies are not far behind at 31%. Therapeutic focus areas have also evolved since the last survey findings, with neurology (44%), cardiovascular (39%), and immune disorders (32%) now outpacing a previous dominance in oncology. Despite the multiple macro challenges they face, the biggest risk to biotechs' operations is the complexity of drug development. Almost three quarters of respondents (73%) ranked this among their top five micro factorsposing the greatest risk to their organisation's operations. The survey highlighted how biotech companies are increasingly embracing digital technologies to improve operations, with 76% of respondents anticipating AI and other technologies will significantly accelerate R&D processes within the next two years. When asked which factors have the most potential to accelerate drug development, 41% of respondents selected AI-enabled asset selection in drug discovery, an increase from 26% in 2023. ION's separate survey of China-based biotechs, was based on 100 respondents. The findings highlighted that the challenges China-based biotechs face align with their global counterparts, most notably funding, and the complexity of drug development and regulations. Cardiovascular and oncology remain the top therapeutic focus areas in China, in contrast to the global shift toward neurology. However, cell therapy, microbiome therapies, and ADCs dominate pipelines across all regions. Respondents in China also report less concern about geopolitical developments and greater confidence in investment and product success. 공지 • Dec 02
Icon plc Announces Results of Its Latest Industry Survey ICON plc announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, and communication gaps. These challenges contribute to significant disruptions at the startup stage, with 55% of respondents reporting that time from site selection to full activation is longer than 5 months, and 39% reporting longer timelines than two years ago. Contract and budget delays are a persistent issue, with 66% of respondents experiencing them frequently. Almost all respondents (92%) identified these as the top areas where both sponsors and contract research organizations (CROs) can improve support. With 47% of respondents rating sponsor and CRO communication as average or poor, this highlights a critical need for site-centricity. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$184, the stock trades at a forward P/E ratio of 21x. Average trailing P/E is 38x in the Life Sciences industry in the US. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$240 per share. Buy Or Sell Opportunity • Oct 25
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.8% to US$178. The fair value is estimated to be US$224, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 3.1% per annum. Earnings are also forecast to grow by 14% per annum over the same time period. Reported Earnings • Oct 24
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: EPS: US$0.03 (down from US$2.38 in 3Q 2024). Revenue: US$2.04b (flat on 3Q 2024). Net income: US$2.36m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 9.7% in 3Q 2024). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) missed analyst estimates by 99%. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to US$193, the stock trades at a forward P/E ratio of 19x. Average trailing P/E is 32x in the Life Sciences industry in the US. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at US$262 per share. 공지 • Sep 24
ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025 ICON Public Limited Company announced that they will report Q3, 2025 results After-Market on Oct 22, 2025 공지 • Sep 22
ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD) ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD) Price Target Changed • Jul 25
Price target increased by 21% to US$213 Up from US$176, the current price target is an average from 15 analysts. New target price is 14% above last closing price of US$187. Stock is down 42% over the past year. The company is forecast to post earnings per share of US$9.50 for next year compared to US$9.60 last year. Reported Earnings • Jul 24
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$2.31 (up from US$1.78 in 2Q 2024). Revenue: US$2.02b (down 4.8% from 2Q 2024). Net income: US$183.0m (up 25% from 2Q 2024). Profit margin: 9.1% (up from 6.9% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 6.5%. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. 공지 • Jul 24
ICON Public Limited Company Updates Earnings Guidance for Full Year 2025 ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$168, the stock trades at a forward P/E ratio of 17x. Average trailing P/E is 36x in the Life Sciences industry in the US. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$251 per share. 공지 • Jun 23
ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025 ICON Public Limited Company announced that they will report Q2, 2025 results After-Market on Jul 23, 2025 공지 • Jun 12
ICON Public Limited Company, Annual General Meeting, Jul 22, 2025 ICON Public Limited Company, Annual General Meeting, Jul 22, 2025. Location: south county business park, leopardstown., dublin 18 Ireland Price Target Changed • May 02
Price target decreased by 12% to US$185 Down from US$210, the current price target is an average from 16 analysts. New target price is 30% above last closing price of US$143. Stock is down 54% over the past year. The company is forecast to post earnings per share of US$9.60 for next year compared to US$9.60 last year. Reported Earnings • May 01
First quarter 2025 earnings: EPS misses analyst expectations First quarter 2025 results: EPS: US$1.91 (down from US$2.27 in 1Q 2024). Revenue: US$2.00b (down 4.3% from 1Q 2024). Net income: US$154.2m (down 18% from 1Q 2024). Profit margin: 7.7% (down from 9.0% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. 공지 • May 01
Icon Public Limited Company Updates Earnings Guidance for Full Year 2025 ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%. Price Target Changed • Apr 10
Price target decreased by 8.4% to US$223 Down from US$243, the current price target is an average from 16 analysts. New target price is 56% above last closing price of US$143. Stock is down 54% over the past year. The company is forecast to post earnings per share of US$10.27 for next year compared to US$9.60 last year. 공지 • Mar 31
ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025 ICON Public Limited Company announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2025 공지 • Feb 22
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025 ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million. Reported Earnings • Feb 20
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: US$9.60 (up from US$7.46 in FY 2023). Revenue: US$8.28b (up 2.0% from FY 2023). Net income: US$791.5m (up 29% from FY 2023). Profit margin: 9.6% (up from 7.5% in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.4%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. 공지 • Feb 20
ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $750 million worth of its shares. ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its shares. 공지 • Feb 12
Robbins LLP Announces Class Action Lawsuit Against ICON PLC Robbins LLP informed stockholders that a class action was filed on behalf of all purchasers of ICON PLC ordinary shares between July 27, 2023 and October 23, 2024. The Allegations: Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand. According to the complaint, during the class period, defendants failed to disclose that: (a) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company's client base; (b) ICON's purported FSP and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the RFPs ICON received from its biotechnology customers during the class period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d) ICON's customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e) ICON's two larger customers were diversifying their CRO providers away from the Company; (f) as a result of (a)-(e) above, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON's services; and (g) that as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the class period and such guidance lacked a reasonable factual basis. 공지 • Jan 30
Icon Portfolio of Ai Tools Drives Clinical Trial Efficiencies ICON plc announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting. ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerate trials, enhance data and optimise operational efficiencies. The centre is supported by an AI Governance Committee, which oversees ethical, legal and data privacy standards in the deployment of new solutions. The latest solutions to be launched are: Submit, which automates the clinical trial document management process. It uses AI to improve compliance, reduce the burden on clinical project teams, and manage documents in an efficient and accurate way based on defined rules. Mapi Research Trust COA leverages AI to remain current with latest Clinical Outcome Assessments (COAs) from public sources in near real-time. It provides comprehensive intelligence to support optimal clinical trial protocols/designs. FORWARD+ is an AI-enabled capability that provides industry-leading visibility into resource demands, allocations and forecasting. FORWARD+ ensures efficient resource management through the clinical trial process. Study Start-up Site Contracts is an AI-enabled capability that streamlines the clinical contract drafting process by leveraging historical clinical contracts in order to create comprehensive near final draft contracts. OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights. Based on its success to date in implementing innovative AI solutions for its customers, ICON plans to further enhance its award-winning capabilities in how AI can drive productivity and efficiencies in clinical trials, with support from Enterprise Ireland. This sustained focus on investment in AI solutions by ICON will support its customers as they look to overcome some of the challenges in realising the potential of AI in drug development. A recent ICON survey of biopharma companies found that 13% of respondents indicated that while AI and digital technologies are being heavily used in single development programs, it is challenging for organizations to systemically incorporate them, possibly due to the complexity of managing such strategic, enterprise-scale digital disruption. 공지 • Jan 29
ICON Public Limited Company to Report Q4, 2024 Results on Feb 19, 2025 ICON Public Limited Company announced that they will report Q4, 2024 results After-Market on Feb 19, 2025 공지 • Jan 15
ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025 ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million.
For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint. 공지 • Jan 08
Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative Disorders ICON plc released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: 'Early, precise and efficient: The methods and technologies advancing Alzheimer's and Parkinson's R&D'. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation. The use of biomarkers can sometimes make a trial longer, more expensive, and slower to enrol patients. However, implementation of biomarker tests could be increasingly implemented to address some of the more resource-intensive eligibility criteria, such as imaging or CSF status. Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only 28% of respondents reported implementing an adaptive trial design of any type, while even fewer reported using historic controls (22%) or master protocol designs (19%), all of which can accelerate patient recruitment. Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (87%) reported that they plan to invest in multiple therapeutic areas or a combination approach. They are also using AI to accelerate R&D, predominantly for the initial steps of the development process. For example, half of respondents who reported using AI or machine learning employ it for hypothesis generation (48%) and lead discovery (50%). Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only 29% of respondents indicated that it was an area that could support and accelerate R&D. 공지 • Dec 18
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer ICON plc announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to customers and further enhance the company's strategy to become the healthcare intelligence partner of choice in the industry. Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$217, the stock trades at a forward P/E ratio of 21x. Average trailing P/E is 44x in the Life Sciences industry in the US. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$403 per share. Price Target Changed • Oct 25
Price target decreased by 18% to US$287 Down from US$352, the current price target is an average from 16 analysts. New target price is 30% above last closing price of US$220. Stock is down 6.3% over the past year. The company is forecast to post earnings per share of US$8.73 for next year compared to US$7.46 last year. 공지 • Oct 25
ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares. ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its shares. Reported Earnings • Oct 24
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: US$2.38 (up from US$1.99 in 3Q 2023). Revenue: US$2.03b (down 1.2% from 3Q 2023). Net income: US$197.1m (up 20% from 3Q 2023). Profit margin: 9.7% (up from 8.0% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.9%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. 공지 • Oct 24
ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024 ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%. 공지 • Sep 27
ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024 ICON Public Limited Company announced that they will report Q3, 2024 results After-Market on Oct 23, 2024 공지 • Aug 15
ICON plc Announces Chief Financial Officer Changes ICON plc announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare’s CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes and oversaw strong financial growth across multiple business lines. Most recently, Nigel was CFO at LetsGetChecked, a global provider of at-home healthcare services. Nigel has a long tenure and a strong track record of success as CFO in a number of large organizations in the life sciences and healthcare services industry. He has successfully led and supported the financial growth of a number of organizations and has a strong background as a CFO of a public company with significant experience in M&A as well as financial processes and systems enhancement. Nigel holds a Bachelor of Science (Accounting) degree and a Master of Accounting degree from Queen’s University Belfast and is also a qualified chartered accountant and a fellow of Chartered Accountants Ireland. Nigel will be based in ICON’s Dublin office and will join ICON early in quarter four this year. The company tanks to its outgoing CFO, Brendan Brennan, for his significant contribution to ICON over the past 18 years. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Jul 31
Chief Financial Officer notifies of intention to sell stock Brendan Brennan intends to sell 26k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of July. If the sale is conducted around the recent share price of US$326, it would amount to US$8.5m. Since December 2023, Brendan has owned 22.11k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Reported Earnings • Jul 25
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: US$1.78 (up from US$1.41 in 2Q 2023). Revenue: US$2.12b (up 4.9% from 2Q 2023). Net income: US$146.9m (up 27% from 2Q 2023). Profit margin: 6.9% (up from 5.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 27%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. 공지 • Jul 25
ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024 ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%. 공지 • Jul 24
ICON Public Limited Company Announces Board Changes ICON Public Limited Company confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director, at its AGM held on July 24, 2024. Ms. Whitaker is an experienced healthcare executive, advisor and director. She currently serves as managing partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, CEO and Chair of the Board of Aerami Therapeutics, and as an operating partner of NewVale Capital, a private equity firm. Ms. Whitaker was previously CEO and director of Novoclem Therapeutics. Earlier in her career, Ms. Whitaker held senior executive leadership positions at Bausch Health, Sanofi, GlaxoSmithKline, and multiple CEO roles for private and public development-stage companies. Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Nykode Therapeutics, Trinity Life Sciences, Byrn Pharma and Bespak. She is a member of the Board of Trustees of the University of North Alabama. She previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals. She holds a BSc in Chemistry and Business from the University of North Alabama. Buy Or Sell Opportunity • Jul 18
Now 21% undervalued Over the last 90 days, the stock has risen 14% to US$328. The fair value is estimated to be US$413, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 7.0% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. 공지 • Jul 02
ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024 ICON Public Limited Company announced that they will report Q2, 2024 results After-Market on Jul 24, 2024 공지 • Jun 13
ICON Public Limited Company, Annual General Meeting, Jul 23, 2024 ICON Public Limited Company, Annual General Meeting, Jul 23, 2024. Location: south county business park, leopardstown, dublin 18 Ireland Recent Insider Transactions Derivative • Jun 08
Chief Administrative Officer notifies of intention to sell stock Diarmaid Cunningham intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of June. If the sale is conducted around the recent share price of US$329, it would amount to US$1.6m. As of today, Diarmaid currently holds no shares directly (This sale likely refers to shares that have not yet been received). There have been no trades via on-market transactions or options from company insiders in the last 12 months. 공지 • May 31
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024 ICON Public Limited Company reaffirmed earnings guidance for the year 2024. Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 million - $8,720 million, representing a year over year increase of 4.4% to 7.4%. Buy Or Sell Opportunity • Apr 26
Now 20% undervalued Over the last 90 days, the stock has risen 13% to US$300. The fair value is estimated to be US$376, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Reported Earnings • Apr 25
First quarter 2024 earnings: EPS exceeds analyst expectations First quarter 2024 results: EPS: US$2.27 (up from US$1.43 in 1Q 2023). Revenue: US$2.09b (up 5.7% from 1Q 2023). Net income: US$187.4m (up 61% from 1Q 2023). Profit margin: 9.0% (up from 5.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.9%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. 
